Compositions and methods comprising anti-NRP2 antibodies

Patent metadata

Field	Value
Publication number	US-12065495-B2
Application number	US-202218048345-A
Country	US
Kind code	B2
Filing date	Oct 20, 2022
Priority date	Apr 6, 2018
Publication date	Aug 20, 2024
Grant date	Aug 20, 2024

Abstract

Provided are antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, for example, human histidyl-tRNA synthetase (HRS), and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.

First claim

The invention claimed is:

1. A therapeutic composition, comprising at least one antibody or antigen-binding fragment thereof that specifically binds to a human neuropilin-2 (NRP2) polypeptide (anti-NRP2 antibody) at an epitope in the neuropilin A2 domain of human NRP2 wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (V H ) sequence that comprises complementary determining region V H CDR1, V H CDR2, and V H CDR3 sequences and a light chain variable region (V L ) sequence that comprises complementary determining region V L CDR1, V L CDR2, and V L CDR3 sequences, wherein:
the V H CDR1, V H CDR2, and V H CDR3 sequences comprise SEQ ID NOs: 77-79, respectively, and the V L CDR1, V L CDR2, and V L CDR3 sequences comprise SEQ ID NOs: 80-82, respectively.

2. The therapeutic composition of claim 1 , wherein the epitope comprises residues 190-265 of human NRP2 as defined by SEQ ID NO:1.

3. The therapeutic composition of claim 2 , wherein the epitope comprises residues L192, T232, T234, P235, E237, D258, and R263 of human NRP2 as defined by SEQ ID NO: 1.

4. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof antagonizes the binding/signaling activity between the NRP2 polypeptide and a plexin receptor and/or semaphorin 3F (SEMA 3F) without substantially modulating the binding/signaling activity between the NRP2 polypeptide and VEGFR3 or VEGF-C.

5. The therapeutic composition of claim 4 , wherein the at least one antibody or antigen-binding fragment thereof selectively inhibits receptor dimerization between the NRP2 polypeptide and plexin A1 without substantially inhibiting dimerization between the NRP2 polypeptide and FLT4 (VEGFR3).

6. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), or IgM Fc domain, optionally a human Fc domain, or a hybrid and/or variant thereof.

7. The therapeutic composition of claim 6 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG Fc domain with high effector function in humans, optionally an IgG1 or IgG3 Fc domain.

8. The therapeutic composition of claim 6 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG Fc domain with low effector function in humans, optionally an IgG2 or IgG4 Fc domain.

9. The therapeutic composition of claim 8 , wherein the at least one antibody or antigen-binding fragment thereof comprises an IgG1 or IgG4 Fc domain, optionally selected from SEQ ID NOs: 116-119.

10. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is a monoclonal antibody.

11. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is a humanized antibody.

12. The therapeutic composition of claim 1 , wherein the at least one antibody or antigen-binding fragment thereof is an Fv fragment, a single chain Fv (scFv) polypeptide, an adnectin, an anticalin, an aptamer, an avimer, a camelid antibody, a designed ankyrin repeat protein (DARPin), a minibody, a nanobody, or a unibody.

13. The therapeutic composition of claim 1 , wherein the composition has a purity of at least about 80%, 85%, 90%, 95%, 98%, or 99% on a protein basis with respect to the at least one antibody or antigen-binding fragment, and is substantially aggregate-free and substantially endotoxin-free.

14. The therapeutic composition of claim 1 , wherein the therapeutic composition is a sterile, injectable solution, optionally suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration.

15. The therapeutic composition of claim 1 , further comprising at least one additional agent selected from one or more of a cancer immunotherapy agent, a chemotherapeutic agent, a hormonal therapeutic agent, and a kinase inhibitor.

Assignees

• Atyr Pharma Inc

Inventors

• Burman Luke G
• Chong Yee Ting (Esther)
• Geng Yanyan
• Greene Leslie Nangle
• Hamel Kristina
• King David
• Menefee Ann
• Rauch Kaitlyn
• Xu Zhiwen
• Zhai Liting

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/72

  Increased effector function due to an Fc-modification · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title